Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IITerminatedDec 14, 2016PAPA/PHEN/PROSTLack of Assurance of Sterility: product produced on a day there was an excursion in environmental monitoring data.Fallon Wellness Pharmacy, L.L.C. · D-0173-2017Class IIITerminatedDec 14, 2016SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE INJECTIONSubpotent Drug: Product has an an out of specification in iron assay analysis found during 18 month stability testing.West-Ward Pharmaceuticals Corp. · D-0172-2017Class IIITerminatedDec 14, 2016Qnasl (beclomethasone dipropionate) Nasal Aerosol 80 McgFailed Content Uniformity: Product was out of specification for spray content uniformity obtained during stability testing.Teva Pharmaceuticals USA · D-0171-2017Class IIITerminatedDec 14, 2016Qnasl (beclomethasone dipropionate) Nasal Aerosol 40 McgFailed Content Uniformity: Product was out of specification for spray content uniformity obtained during stability testing.Teva Pharmaceuticals USA · D-0170-2017Class IIITerminatedDec 14, 20165% Lidocaine HCL and 7.5% Dextrose InjectionFailed Stability Specifications: The recalled lots did not meet the specification for color and pH throughout shelf life.Hospira Inc. · D-0169-2017Class IITerminatedDec 7, 2016Phenazopyridine Hydrochloride TabletsCGMP Deviations: manufactured under practices which may result in assay or content uniformity failures.Nationwide Laboratories, LLC · D-0168-2017Class IITerminatedDec 7, 2016Phenazopyridine Hydrochloride TabletsCGMP Deviations: manufactured under practices which may result in assay or content uniformity failures.Nationwide Laboratories, LLC · D-0167-2017Class IITerminatedDec 7, 2016Salsalate TabletsCGMP Deviations: manufactured under practices which may result in assay or content uniformity failures.Nationwide Laboratories, LLC · D-0166-2017Class IITerminatedDec 7, 2016Salsalate TabletsCGMP Deviations: manufactured under practices which may result in assay or content uniformity failures.Nationwide Laboratories, LLC · D-0165-2017Class IITerminatedDec 7, 2016Ondansetron HCI APIMicrobial Contamination of Non-Sterile ProductCadila Pharmaceuticals Limited · D-0164-2017Class IITerminatedDec 7, 2016Metformin Hydrochloride TabletsPresence of Foreign Tablets/Capsules; report of Amlodipine Tablets found in 1000 count bottles of Metformin Hydrochloride Tablets USPAscend Laboratories LLC · D-0163-2017Class IITerminatedDec 7, 2016Phenazopyridine Hydrochloride TabletsCGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failuresBurel Pharmaceuticals Inc · D-0162-2017Class IITerminatedDec 7, 2016Phenazopyridine Hydrochloride TabletsCGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failuresBurel Pharmaceuticals Inc · D-0161-2017Class IITerminatedDec 7, 2016Indiomin MB URINARY ANTISEPTICCGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failuresBurel Pharmaceuticals Inc · D-0160-2017Class IITerminatedDec 7, 2016AZUPHEN MB URINARY ANTISEPTIC CapsulesCGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failuresBurel Pharmaceuticals Inc · D-0159-2017Class IITerminatedDec 7, 2016UROPHEN MB URINARY ANTISEPTIC TabletsCGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failuresBurel Pharmaceuticals Inc · D-0158-2017Class IITerminatedDec 7, 2016URAMIT MB URINARY ANTISEPTIC CapsulesCGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failuresBurel Pharmaceuticals Inc · D-0157-2017Class IITerminatedDec 7, 2016UROLET MB URINARY ANTISEPTICCGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failuresBurel Pharmaceuticals Inc · D-0156-2017Class IITerminatedDec 7, 2016Hyolev MB URINARY ANTISEPTIC TabletsCGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failuresBurel Pharmaceuticals Inc · D-0155-2017Class IITerminatedDec 7, 2016Travoprost Ophthalmic Solution USPLack of Assurance of Sterility; damage to the internal portion of the dropper tip portion of the containerPar Pharmaceutical, Inc. · D-0154-2017Class IITerminatedNov 30, 2016Phenobarbital TabletsFailed Dissolution Specifications: Phenobarbital Tablets have an out of specification for dissolution at the 12 month stability time pointWest-Ward Pharmaceuticals Corp. · D-1045-2017Class IITerminatedNov 30, 2016Fentanyl Citrate InjectionLack of Assurance of Sterility: Complaints of broken tips on the ampules.Hospira Inc. · D-0153-2017Class IITerminatedNov 30, 2016Desoximetasone Ointment USPFailed Stability Specifications; out-of specification value for homogeneity / phase separation.Akorn Inc · D-0152-2017Class IIITerminatedNov 30, 2016Diltiazem HCl Extended-release CapsulesFailed Impurities/Degradation Specifications: OOS results for known compound.Mylan Pharmaceuticals Inc. · D-0151-2017Class IITerminatedNov 30, 2016LEVOXYL(R)SuperpotentPfizer Inc. · D-0150-2017Class IIITerminatedNov 30, 2016BuPROPion Hydrochloride Extended-Release TabletsFailed Dissolution Specifications: Product did not meet dissolution specification at an intermediate time point.Zydus Pharmaceuticals USA Inc · D-0149-2017Class IIITerminatedNov 30, 2016KENALOGFailed Stability Specifications: Low Out of Specification results for alcohol content.Sun Pharmaceutical Industries, Inc. · D-0148-2017Class IIITerminatedNov 30, 2016Amoxicillin for Oral suspensionLabeling: Label Error on Declared Strength: Some bottles miss a color coded panel where the strength of the product is typically displayed.West-Ward Pharmaceuticals Corp. · D-0147-2017Class IITerminatedNov 30, 2016Lactulose SolutionMicrobial Contamination of Non-Sterile Products: bulk solution tested positive for the presence of the bacteria, Burkholderia cepacia.VistaPharm, Inc. · D-0146-2017Class IIITerminatedNov 30, 2016Ceftriaxone for InjectionLabeling: Missing LabelSandoz Inc · D-0145-2017Class IIITerminatedNov 30, 2016AHP NIFEdipine CapsulesPresence of Foreign Tablets/CapsulesAmerisource Health Services · D-0144-2017Class IIITerminatedNov 30, 2016NIFEdipine Capsules USPPresence of Foreign Tablets/CapsulesActavis Elizabeth LLC · D-0143-2017Class IIITerminatedNov 23, 2016Zeasorb AFLabeling Not Elsewhere Classified: front labels have the incorrect NDC or 0145-1506-01 instead of the correct NDC of 0145-1506-05 and some back labels have the incorrect...GSK Consumer Healthcare · D-0142-2017Class IITerminatedNov 23, 2016L-Cysteine Hydrochloride InjectionLack of Assurance of Sterility: a recent FDA inspection at the manufacturing firm raised concerns that the product sterility may be compromised.Sandoz Inc · D-0141-2017Class IITerminatedNov 23, 2016L-Cysteine Hydrochloride InjectionLack of Assurance of Sterility: a recent FDA inspection at the manufacturing firm raised concerns that the product sterility may be compromised.Sandoz Inc · D-0140-2017Class IIITerminatedNov 23, 2016FIRST Omeprazole 2mg/mL in FIRST PPI Suspension Compounding KitLabeling: Label error on declared strength. Package Insert -Error in the Description section of the package insert refers to the strength as 3mg per mL; however it...CutisPharma, Inc. · D-0139-2017Class IIITerminatedNov 23, 2016FIRST Omeprazole 2mg/mL in FIRST PPI Suspension Compounding KitLabeling: Label error on declared strength. Package Insert -Error in the Description section of the package insert refers to the strength as 3mg per mL; however it...CutisPharma, Inc. · D-0138-2017Class IIITerminatedNov 23, 2016Bupropion Hydrochloride Extended-Release TabletsFailed Dissolution Specifications: The firm was notified that there was a dissolution out of specification result on the 6 month stability samples.Amerisource Health Services · D-0137-2017Class IIITerminatedNov 16, 2016Clonazepam TabletsFailed Impurities/Degradation Specifications: out of specification result for Clonazepam Related Compound (RC) A (a known impurity) at 16 month timepoint.Mylan Institutional, Inc. (d.b.a. UDL Laboratories) · D-0136-2017Class IIITerminatedNov 16, 2016Clonazepam TabletsFailed Impurities/Degradation Specifications: out of specification result for Clonazepam Related Compound (RC) A (a known impurity) at 15 month timepoint.Mylan Institutional, Inc. (d.b.a. UDL Laboratories) · D-0135-2017

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.